New pill challenges standard combo in fight against recurrent brain cancer
NCT ID NCT07104032
Summary
This study is testing whether a new oral drug called tirabrutinib works better than the current standard combination therapy (rituximab and temozolomide) for people whose primary brain lymphoma has come back or didn't respond to prior treatment. It will involve about 132 participants who have already had at least one prior treatment. The main goal is to see which treatment keeps the cancer from growing for a longer period of time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
HonorHealth Cancer Center
RECRUITINGScottsdale, Arizona, 85251, United States
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
-
UPMC Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
-
Yale Cancer Center
RECRUITINGNew Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.